Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multimodality Management in Risk-Stratified Lung-Limited Metastatic Colorectal Cancer
NCT03599752Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jul 2018
- Primary completion
- Jan 2030
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial in colorectal cancer (CRC) (4 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Recurrence-free survival at 2 years and Overall survival at 2 years. Started Jul 2018; status: active, not recruiting.
02
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT03599752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03599752.